Press Releases Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Market Closed - Toronto S.E. Other stock markets 04:00:00 2024-05-17 pm EDT			5-day change	1st Jan Change
2.93 ^CAD	-9.01%		-2.66%	+166.36%

May. 14	Cardiol Therapeutics Says Phase II ARCHER Trial Presented at World Congress on Acute Heart Failure	MT
Apr. 22	HC Wainwright Starts Cardiol Therapeutics With Buy Rating, $9 Price Target	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

CARDIOL THERAPEUTICS : CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE MONTHS ENDED MARCH 31, 2024 (EXPRESSED IN CANADIAN DOLLARS) - Form 6-K	May. 14	PU
Cardiol Therapeutics Announces Phase II ARCHER Trial Presented at the World Congress on Acute Heart Failure 2024	May. 14	NE
Cardiol Therapeutics : Notice of Meeting and Record Date - Form 6-K	Apr. 26	PU
Cardiol Therapeutics Announces Year-End 2023 Update on Operations	Apr. 02	NE
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis	Feb. 21	NE
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis	Feb. 15	NE
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market	Jan. 24	NE
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis	Jan. 09	NE
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot	Dec. 05	NE
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases	Nov. 16	NE
CARDIOL THERAPEUTICS : CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023 - Form 6-K	Nov. 14	PU
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis	Nov. 01	NE
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	23-10-23	AQ
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement	23-10-20	NE
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases	23-10-13	AQ
Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol	23-10-11	AQ
Cardiol Therapeutics : MATERIAL CHANGE REPORT - Form 6-K	23-10-11	PU
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction	23-10-10	NE
Cardiol Therapeutics On Track To Provide New Standard Of Care For Cardiovascular Diseases ($CRDL)	23-10-10	AQ
Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)	23-10-02	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cardiol Therapeutics Inc.

Equities

CRDL

CA14161Y2006

Press Releases

Filters